October 2024
The global leuprorelin drugs market size was estimated at US$ 2.60 billion in 2023 and is projected to grow to US$ 4.78 billion by 2034, rising at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2034. The demand for leuprorelin drugs is growing in the market because these drugs are highly useful in various hormone-related health problems.
Unlock Infinite Advantages: Subscribe to Annual Membership
The FDA has authorized leuprolide as a gonadotropin-releasing hormone (GnRH) agonist for the treatment of endometriosis, breast cancer, paraphilia, hypersexuality, central precocious puberty, and prostate cancer. The leuprorelin drugs market is growing as a result of the usage of these medications in all applications. The new generation's central precocious puberty is increasing as a result of consuming foods like eggs, milk, poultry, and other foods made by injecting hormones. In addition, recent years have seen a significant increase in transgender operations and the usage of leuprorelin medications for hormone treatment in transgender people who are male to female.
In recent years, the number of gender-affirming surgeries has grown, and the number is estimated to grow significantly in the future. Hormone therapy is a common practice in such cases, and leuprorelin drugs are used for that. These are used to suppress the production of testosterone and estrogen, which is a common practice in gender-affirming surgeries. As more and more people are going to have the surgeries, the demand for leuprorelin drugs is going to grow, ultimately impacting the leuprorelin drugs market positively.
For instance,
Leuprorelin medications have a number of negative effects that may deter many people from using them. Certain metabolic conditions, including diabetes or hyperglycemia (high blood glucose), hyperlipidemia, cirrhosis, or non-alcoholic liver disease, may be exacerbated or brought on by leuprolide.
North America dominated the leuprorelin drugs market in 2023.
The market is strongly growing in the region due to advanced healthcare infrastructure and awareness among citizens. Apart from this, due to the growing cases of prostate cancer and breast cancer in the region, organizations and the government are taking initiatives to provide proper healthcare.
The U.S. is expected to see 609,820 cancer deaths and 1,958,310 new cancer cases in 2023. The American Cancer Society projects that there will be around 299,010 new instances of prostate cancer and 35,250 prostate cancer-related deaths in the United States in 2024. Approximately one in eight men may receive a prostate cancer diagnosis at some point in their lives. However, a man's age, race or ethnicity, and other characteristics can all affect his risk of prostate cancer. According to the latest data available, 42,211 females in the U.S. lost their lives to breast cancer in 2022, while 272,454 new cases of the disease were recorded in 2021.
One of the most prevalent malignancies to be identified, it is also one of the main causes of cancer-related deaths for men in Canada. Among other things, early identification and therapy may have an impact on prostate cancer survival. According to Canadian statistics, 1 in 8 men (12%) may receive a prostate cancer diagnosis at some point in their lives.
Asia Pacific is expected to grow at the fastest rate during the forecast period.
The leuprorelin drugs market is growing strongly due to growing investments in healthcare and growing cases of prostate and breast cancer. Apart from this, Asia Pacific consists of 2nd and 3rd largest pharmaceutical industries known for the production of drugs on a large scale for exporting worldwide. This indicates that leuprorelin drugs may be produced on a large scale in the region. The major countries that contribute to the growth of the leuprorelin drugs market include China, India, Japan, and South Korea.
In India, the cases of prostate cancer were 43,691 in 2022, and testis cancer cases were 4521. And the cases of breast cancer in India in 2022 were 221,757. It is estimated that the cases are going to rise significantly in the future, which will increase the demand for leuprorelin drugs in India.
By type, the injections segment held the largest share of the leuprorelin drugs market and is estimated to remain dominant during the forecast period. There are several advantages of giving drugs using injections, which promote the growth of the segment. Injections are useful in uniformly spreading drugs in the desired location. The medication acts quickly compared to tablets. Due to the high demand for injections, pharmaceutical companies produce them more often.
For instance,
By application, the prostate cancer segment dominated the leuprorelin drugs market and is estimated to remain dominant during the forecast period. The fifth most common cause of death globally and the second most common cancer diagnosis in males is prostate cancer. Prostate cancer cells develop more rapidly when male hormones like testosterone are present. The progression of prostate cancer can be slowed by lowering the body's testosterone levels. People with late-stage prostate cancer often benefit from hormone therapy, including Lupron, when used in conjunction with other treatments.
For instance,
By Type
By Application
By Region
October 2024
April 2024
April 2024
April 2024
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts